Shares of HENLIUS (02696) plummeted 10.53% in the intraday trading session on Thursday, following the rejection of Chinese conglomerate Fosun International's buyout offer by Hong Kong shareholders.
The rejected offer, which valued the drugmaker at HK$13.37 billion ($1.72 billion), proposed a buyout price of HK$24.60 per share. Fosun unit Shanghai Fosun Pharmaceutical, which already holds a 59.6% stake in HENLIUS, failed to secure the requisite majority approval from H-class shareholders for the privatization proposal.
The sharp decline in HENLIUS's stock price reflects investors' disappointment with the failed buyout attempt. The rejection of the offer raises concerns about the company's future prospects and potential challenges in securing alternative funding or strategic partnerships.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。